User: Guest  Login
Title:

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

Document type:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Author(s):
Hochhaus, A; O'Brien, SG; Guilhot, F; Druker, BJ; Branford, S; Foroni, L; Goldman, JM; Müller, MC; Radich, JP; Rudoltz, M; Mone, M; Gathmann, I; Hughes, TP; Larson, RA
Abstract:
Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n=553) or interferon-alpha (IFN) plus cytarabine (n=553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth yea...     »
Journal title abbreviation:
Leukemia
Year:
2009
Journal volume:
23
Journal issue:
6
Pages contribution:
1054-61
Language:
eng
Fulltext / DOI:
doi:10.1038/leu.2009.38
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/19282833
Print-ISSN:
0887-6924
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX